David N Araiza, MD
Family Practice · Stockton
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
- Since medical school
- 6 years
- Graduated 2020
Offices
3 locations · Community Medical Centers, Inc. · 47 clinicians in this group
Looking this up.
Hospitals listed: St Joseph'S Medical Center of Stockton. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Araiza’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A186047 · Current
Licensed to practise in California · since 2023 · expires 2027-07-31 · University of California, Davis School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Family Medicine - Family Medicine
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- St Joseph'S Medical Center of StocktonStockton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 67% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.08, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.34, Oct 2024 – Sep 2025
See every measure and the patient survey for St Joseph'S Medical Center of Stockton
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 4 the same, 0 worse of 6 measures. Readmissions: 0 better, 6 the same, 2 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.08 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.34 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.51 (0.54 to 2.47) · 1,424 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.06 (0.78 to 1.33) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.22 (98.08 to 180.36) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 127 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 98 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.9 · 257 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.2 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 18.4 · 405 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9 · 337 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 3,812 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.09 to 0.49) · 6,528 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,304 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.48 (1.49 to 5.48) · 1,467 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.27 (0 to 2.79) · 464 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.22 (0.81 to 3.64) · 1,404 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.16 (1.3 to 13.02) · 455 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.22 (1.5 to 8.93) · 456 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.24 (0.78 to 3.71) · 262 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.03 (0.53 to 1.53) · 6,521 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.537 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.486 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.646 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 484 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.9 · 878 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 22.2 · 265 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 17.1 · 493 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 407 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 615 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 14.1 · 184 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.4 · 248 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.6 to 17.6) · 164 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 290 cases | No different | Jan 2024 – Dec 2024 |
What patients said (541 patients answered, 14% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 41% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 51% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Medicaid work
$271,784 in 2024
Medicaid paid $271,784 for 6,678 billed services this clinician did in 2024, up to 68 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 1,713 | $271,070 |
| Return visit (30+ min) | 394 | $365 |
| Short return visit (20+ min) | 1,067 | $262 |
| Brief emotional/behavioral assessment (eg, depression inventory, attention-deficit/hyperactivity disorder [ADHD] scale), with scoring and documentation, per standardized instrument | 962 | $88 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 1,060 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 48 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 949 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 156 | $0 |
| Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; capable of being read by direct optical observation only (eg, utilizing immunoassay [eg, dipsticks, cups, cards, or cartridges]), includes sample validation when performed, per date of service | 161 | $0 |
| Alcohol (ethanol); breath | 116 | $0 |
| Blood glucose (sugar) level | 12 | $0 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 27 | $0 |
| 2024 | 6,678 | 13 | 68 | $271,784 |
| 2023 | 1,710 | 8 | 49 | $91,275 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 579 | $90,906 |
| Short return visit (20+ min) | 394 | $334 |
| Brief emotional/behavioral assessment (eg, depression inventory, attention-deficit/hyperactivity disorder [ADHD] scale), with scoring and documentation, per standardized instrument | 184 | $36 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 258 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 12 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 236 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 34 | $0 |
| Return visit (30+ min) | 13 | $0 |
Drugs they prescribed that Part D paid
$114,078
Pharmacies billed $114,078 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
480 generic and 122 brand-name prescriptions · $114,078 in drug cost · 17 antibiotic prescriptions · 12 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Synjardy | 31 | $23,520 | $759 |
| Rybelsus | 16 | $16,069 | $1,004 |
| Jardiance | 12 | $13,978 | $1,165 |
| Breo Ellipta | 12 | $4,780 | $398 |
| Buprenorphine-Naloxone | 45 | $2,729 | $61 |
See all 17 drugs
| Synjardy | 31 | $23,520 | $759 |
| Rybelsus | 16 | $16,069 | $1,004 |
| Jardiance | 12 | $13,978 | $1,165 |
| Breo Ellipta | 12 | $4,780 | $398 |
| Buprenorphine-Naloxone | 45 | $2,729 | $61 |
| Atorvastatin | 31 | $387 | $12 |
| Tamsulosin | 32 | $386 | $12 |
| Losartan | 35 | $324 | $9 |
| Gabapentin | 22 | $284 | $13 |
| Escitalopram | 21 | $248 | $12 |
| Losartan-Hydrochlorothiazide | 15 | $164 | $11 |
| Hydroxyzine | 11 | $150 | $14 |
| Pantoprazole | 12 | $123 | $10 |
| Amlodipine Besylate | 22 | $121 | $5 |
| Lisinopril | 21 | $104 | $5 |
| Famotidine | 12 | $87 | $7 |
| Meloxicam | 15 | $38 | $3 |
Year by year
| 2024 | 602 | 122 | None | 20% | $114,078 |
| 2023 | 494 | 102 | 0% (0) | None | $158,376 |
| 2022 | 384 | 54 | 0% (0) | None | $72,781 |
| 2021 | 216 | 36 | 0% (0) | None | $25,882 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Eliquis | 12 | $17,413 | $1,451 |
| Symbicort | 19 | $8,031 | $423 |
| Synjardy | 11 | $6,691 | $608 |
| Atorvastatin | 58 | $1,250 | $22 |
| Losartan | 49 | $1,079 | $22 |
| Diclofenac | 34 | $921 | $27 |
| Tamsulosin | 12 | $570 | $48 |
| Buprenorphine-Naloxone | 12 | $541 | $45 |
| Metoprolol | 12 | $446 | $37 |
| Digoxin | 12 | $314 | $26 |
| Amlodipine Besylate | 15 | $246 | $16 |
| Lisinopril | 11 | $217 | $20 |
| Meloxicam | 16 | $180 | $11 |
| Hydrochlorothiazide | 19 | $167 | $9 |
| Metformin | 11 | $81 | $7 |
2022: 10 drugs
| Ozempic | 16 | $16,347 | $1,022 |
| Eliquis | 14 | $14,769 | $1,055 |
| Atorvastatin | 35 | $548 | $16 |
| Tamsulosin | 15 | $318 | $21 |
| Lisinopril | 30 | $225 | $8 |
| Metoprolol | 12 | $211 | $18 |
| Hydrochlorothiazide | 33 | $174 | $5 |
| Amlodipine Besylate | 18 | $159 | $9 |
| Meloxicam | 12 | $138 | $11 |
| Losartan | 20 | $104 | $5 |
2021: 3 drugs
| Diclofenac | 15 | $446 | $30 |
| Atorvastatin | 13 | $188 | $14 |
| Losartan | 12 | $90 | $7 |
Money from drug and device companies
$127 in 2025
| 2025 | 1 | 2 | None | $127 |
| 2024 | 3 | 4 | None | $321 |
| 2023 | 1 | 1 | None | $22 |
| 2022 | 2 | 2 | None | $42 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Mavyret | $127 | 2 payments
|
See all 2 published payments
| Abbvie | Meals · 2025-08-09 | Mavyret | $25 |
| Abbvie | Meals · 2025-05-08 | Mavyret | $101 |
See earlier years (2024, 2023, 2022)
2024: $321
| ViiV Healthcare | Cabenuva | $121 | 2 payments
|
| Dexcom | Dexcom G6 Transmitter | $106 | 1 payment
|
| Abbvie | Mavyret | $94 | 1 payment
|
2023: $22
| Indivior | Sublocade | $22 | 1 payment
|
2022: $42
| GlaxoSmithKline | Bexsero | $22 | 1 payment
|
| Boston Scientific | General - Tachy | $20 | 1 payment
|
Professional record
- NPI
- 1477178465
- Licence
- CA A186047California A186047: Current · expires 2027-07-31
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 423 S San Joaquin St, Stockton, CA, 95203
- NPI first listed
- 2020-06-15
- NPI last updated
- 2023-08-04
- NPI record certified
- 2023-08-04
This is when the NPI record was last certified, not a medical board exam.